GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Buy GILD
up 309.98 %

Gilead Sciences, Inc. (GILD) rated Buy with price target $137 by Maxim Group

Posted on: Wednesday,  Oct 28, 2015  2:25 PM ET by Maxim Group

Maxim Group rated Buy Gilead Sciences, Inc. (NASDAQ: GILD) on 10/28/2015. Previously Maxim Group rated Buy Gilead Sciences, Inc. (NASDAQ: GILD) on
07/17/2012., when the stock price was $26.34. Since then, Gilead Sciences, Inc. has gained 309.98% as of 10/28/2015's recent price of $107.99.
If you would have followed the previous Maxim Group's recommendation on GILD, you would have gained 309.98% of your investment in 1198 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2015 2:25 PM Buy
None
106.76 137.00
as of 8/27/2015
1 Week down  -5.63 %
1 Month down  -11.63 %
3 Months down  -0.68 %
1 YTD up  43.79 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/5/2014 9:25 AM Buy
None
78.15 101.00
1/2/2014 9:25 AM Buy
None
75.45 98.00
4/22/2013 2:25 PM Buy
None
53.79 97.00
3/25/2013 9:25 AM Buy
None
46.00 48.00
10/9/2012 8:25 AM Buy
None
34.52 41.50
7/18/2012 8:25 AM Buy
None
26.27 35.00
7/17/2012 8:25 AM Buy
None
26.34 35.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy